CERo Therapeutics Holdings, Inc. - Common Stock CERO 深 沪
等待开盘 09-30 09:30:00 美东时间
5.25
-0.140
-2.60%
华盛通- 最 高5.2969
- 今 开5.25
- 成交量 6.94万股
- 最 低 5.0306
- 昨 收 5.39
- 总市值 202.70万
- 52周最高 895.40
- 市盈率 静 --
- 换手率 17.98%
- 52周最低 4.2701
- 委 比 5.88%
- 总股本 38.61万
- 历史最高 24760.00
- 量 比 0.61
- 振 幅 4.94%
- 历史最低 5.0306
- 每 手 1
- 风险率 114.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CERo Therapeutics Doses Third Patient In Phase 1 AML Trial Of CER-1236
Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohortSOUTH SAN FRANCISCO, Calif, Sept. 22,
09-22 21:18
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort
<p>CERo Therapeutics Holdings, Inc. has dosed the third patient in the starting dose cohort of its Phase 1 clinical trial for CER-1236 in acute myeloid leukemia (AML). The company anticipates additional results from the second dosing of the second patient. Stephen Strickland, Jr., M.D., MSCI, commented on the milestone, highlighting the importance of the safety and pharmacokinetic data gathered. The Phase 1/1b study aims to evaluate the safety, t...
09-22 13:15
For The FY 2025, Broadwind Expects Revenues In A Range Of $145M To $155M
CICERO, Ill., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Broadwind (NASDAQ:BWEN, or the "Company"))), a diversified precision manufacturer of specialized components and equipment serving global markets, today announced the
09-11 04:22
Top 3 Health Care Stocks You'll Regret Missing In Q3
The most oversold stocks in the health care sector presents an opportunity to b...
09-09 21:12
CERo Therapeutics Secures U.S. And Japanese Patents For CER-1236
Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technologySOUTH SAN FRANSCISCO, Calif., Sept. 09, 2025 (GLOBE
09-09 20:18
CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041
CERo Therapeutics Holdings, Inc.宣布，美国专利和商标局允许其申请19/019,111，将为CER-1236提供至2041年的保护。日本专利的获得使国际专利总数达18项，另2项申请中。 CEO称知识产权强劲，临床试验进展顺利。
09-09 12:15
CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia
CERo Therapeutics Holdings, Inc. announced that it has administered the second dose to the second patient in the first cohort of its Phase 1 CER-1236 clinical trial for acute myeloid leukemia (AML). The Institutional Review Board (IRB) approved a multi-dose intensification after reviewing initial pharmacokinetic data, effectively doubling the cell product infusion. The company aims to evaluate the safety and feasibility of multiple infusions and ...
09-08 12:45
美股大行评级 | 潜在涨幅65.5%！花旗上调Braze目标价至52美元，维持"买入"评级
今日重点评级关注：花旗：维持Braze"买入"评级，目标价从50美元升至52美元；花旗：维持Docusign"买入"评级，目标价从115美元升至120美元
09-08 10:23
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target
D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price target.
09-06 02:11
CERo Therapeutics Gains Fast Track for AML Drug
CERo Therapeutics Holdings ( ($CERO) ) has issued an update. On September 5, 20...
09-05 20:57
